NCT03490370

Brief Summary

Non-alcoholic steato-hepatitis (NASH) affects up to 3% of the population and leads to liver cirrhosis, hepatocellular carcinoma (HCC) and death. The only known treatment is weight loss and exercise. Many patients cannot or will not achieve this with conventional means. The pathogenic process of the disease is insulin resistance which can be reversed relatively quickly with intense exercise or electrical stimulation of muscle. Most patients cannot achieve or sustain the level of aerobic exercise required; resistance exercise is more sustainable and similarly effective. The aim of this pilot study is to investigate whether electro-muscle stimulation, designed to emulate resistance exercise, resolves NASH in patients and moves them to a less dangerous metabolic steady state which should be easier to maintain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 27, 2018

Completed
7 days until next milestone

Study Start

First participant enrolled

April 3, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 6, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2018

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 6, 2020

Completed
Last Updated

February 27, 2020

Status Verified

February 1, 2020

Enrollment Period

8 months

First QC Date

March 27, 2018

Last Update Submit

February 25, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Can electro-stimulated muscle activity demonstrate improvement in insulin resistance.

    Change from baseline of frequent sampled Oral Glucose Tolerance Testing (fsOGTT) to end of treatment

    10 months

Secondary Outcomes (1)

  • Can electro-stimulated muscle activity demonstrate improvement in hepatic steatosis

    10 months

Study Arms (1)

Electronic Muscle Stimulation Activity

EXPERIMENTAL

Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.

Device: Electro-muscular stimulation using NeuroTrac MyoPlus 2/4

Interventions

In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.

Electronic Muscle Stimulation Activity

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male/ Female aged 18 - 75
  • Able to give informed consent
  • Biopsy proven NASH with a NAS (NAFLD activity score) activity score equal to or greater than 3
  • A single hepatic diagnosis.

You may not qualify if:

  • Presence of other causes of Chronic Liver Disease
  • Currently or previously decompensated liver disease (ascites, encephalopathy or variceal bleeding)
  • Hepatocellular carcinoma (current or previous)
  • Malignancy - of any sort except basal cell carcinoma
  • Unstable co morbid disease
  • Known HIV positive
  • Limb amputation
  • Implanted electrical device
  • Pregnancy, breastfeeding or undertaking fertility treatment
  • Alcohol intake above 14 units a week
  • Unable to give informed consent
  • Unable to attend required study visits.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NHS Tayside

Dundee, United Kingdom

Location

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseaseInsulin Resistance

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • John Dillon, MD

    NHS Tayside

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Proof of concept study.
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 27, 2018

First Posted

April 6, 2018

Study Start

April 3, 2018

Primary Completion

November 30, 2018

Study Completion

February 6, 2020

Last Updated

February 27, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations